Rubius Therapeutics RUBY Stock
0 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
0 USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Rubius Therapeutics Price Chart
Rubius Therapeutics RUBY Financial and Trading Overview
| Rubius Therapeutics stock price | USD |
| Previous Close | 0.02 USD |
| Open | 0.02 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 800 |
| Day's Range | 0.02 - 0.02 USD |
| 52 Week Range | 0.01 - 1.46 USD |
| Volume | 53.4K USD |
| Avg. Volume | 477.02K USD |
| Market Cap | 1.81M USD |
| Beta (5Y Monthly) | 2.385982 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1 USD |
RUBY Valuation Measures
| Enterprise Value | -12029364 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.020408163 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.119760476 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.099 |
Trading Information
Rubius Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.385982 |
| 52-Week Change | -97.85% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.46 USD |
| 52 Week Low | 0.01 USD |
| 50-Day Moving Average | 0.02 USD |
| 200-Day Moving Average | 0.2 USD |
RUBY Share Statistics
| Avg. Volume (3 month) | 477.02K USD |
| Avg. Daily Volume (10-Days) | 130.94K USD |
| Shares Outstanding | 90.48M |
| Float | 85.39M |
| Short Ratio | 0.49 |
| % Held by Insiders | 5.49% |
| % Held by Institutions | 53.68% |
| Shares Short | 1.53M |
| Short % of Float | 3.87% |
| Short % of Shares Outstanding | 1.69% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.63% |
| Return on Equity (ttm) | -185.30% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -120995000 USD |
| Net Income Avi to Common (ttm) | -179666000 USD |
| Diluted EPS (ttm) | -2.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.87M USD |
| Total Cash Per Share (mrq) | 0.16 USD |
| Total Debt (mrq) | 1.1M USD |
| Total Debt/Equity (mrq) | 7.27 USD |
| Current Ratio (mrq) | 2.544 |
| Book Value Per Share (mrq) | 0.167 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -150142000 USD |
| Levered Free Cash Flow (ttm) | -85372000 USD |
Profile of Rubius Therapeutics
| Country | United States |
| State | MA |
| City | Foxborough |
| Address | 124 Washington Street |
| ZIP | 02035 |
| Phone | 508 543 1720 |
| Website | https://www.rubiustx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6 |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Q&A For Rubius Therapeutics Stock
What is a current RUBY stock price?
Rubius Therapeutics RUBY stock price today per share is USD.
How to purchase Rubius Therapeutics stock?
You can buy RUBY shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rubius Therapeutics?
The stock symbol or ticker of Rubius Therapeutics is RUBY.
Which industry does the Rubius Therapeutics company belong to?
The Rubius Therapeutics industry is Biotechnology.
How many shares does Rubius Therapeutics have in circulation?
The max supply of Rubius Therapeutics shares is 0.
What is Rubius Therapeutics Price to Earnings Ratio (PE Ratio)?
Rubius Therapeutics PE Ratio is 0.00000000 now.
What was Rubius Therapeutics earnings per share over the trailing 12 months (TTM)?
Rubius Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Rubius Therapeutics company belong to?
The Rubius Therapeutics sector is Healthcare.
Rubius Therapeutics RUBY included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17376.52 USD — |
+0.06
|
9.4B USD — | 17256.2 USD — | 17425.17 USD — | — - | 9.4B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4151.81 USD — |
-0.14
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8557 USD — |
+0.73
|
— — | 8441.28 USD — | 8559.03 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4211.86 USD — |
+0.65
|
— — | 4128.39 USD — | 4219.13 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 937.2 USD — |
+0.66
|
— — | 922.07 USD — | 938.35 USD — | — - | — — |
- {{ link.label }} {{link}}